LOS
ANGELES, Sept. 20, 2023 /PRNewswire/ -- Aadi
Bioscience, Inc. (NASDAQ: AADI), a biopharmaceutical company
focused on developing and commercializing precision therapies for
patients with mTOR pathway alterations, today announced that four
abstracts have been selected for presentation at the upcoming 2023
AACR-NCI-EORTC International Conference on Molecular Targets and
Cancer Therapeutics, taking place October
11-15, 2023 in Boston,
MA.
The presentations include four posters: a Trials-in-Progress
(TiP) update from the PRECISION1 trial in TSC1/2 alterations, two
real-world clinical genomic analyses, and one preclinical study
of nab-sirolimus combinations in breast cancer
xenograft models.
Poster Presentation Details:
Title: "Evaluation of nab-sirolimus in
combination with PI3K pathway inhibitors to overcome PI3K/mTOR
resistance in PI3K-mutant breast cancer cell
lines"
Poster Number: A117
Session Title: Poster Session A
Date/Time: Thursday, October 12,
2023, 12:30 pm-4:00 pm
Authors: Sean Wallace, PhD, Khine Nyein Myint, PhD, Shihe Hou, PhD, Maria Zalath, BA, Andrew Kwon, PhD, Brian
McMorran, PhD, Igor Vivanco,
PhD
Title: "Phase 2, Multicenter, Open-label Basket Trial
of nab-Sirolimus for Malignant Solid Tumors Harboring Pathogenic
Inactivating Alterations in TSC1 and TSC2 (PRECISION1)"
Poster Number: LB_B12
Session Title: Poster Session B
Date/Time: Friday, October 13,
2023, 12:30 pm-4:00 pm
Authors: Candace Haddox, MD;
Gopa Iyer, MD; Michael J. Demeure, MD; Li Ding, MS, MA; Anita
N. Schmid, PhD; Willis H.
Navarro, MD; David J.
Kwiatkowski, MD, PhD; Jordi Rodon
Ahnert, MD, PhD
Title: "Real-world (RW) characterization and frequency
of TSC1 and/or TSC2 alterations collected from tumor tissue and
liquid biopsies from the Tempus genomic database in patients with
advanced cancer"
Poster Number: B003
Session Title: Poster Session B
Date/Time: Friday, October 13,
2023, 12:30 pm-4:00 pm
Authors: David J. Kwiatkowski, MD, PhD, Norma A. Palma, PhD, Willis H. Navarro, MD, Gopa Iyer, MD
Title: "Inactivating TSC1 and TSC2 alterations,
co-mutations, and genomic instability in advanced cancers: Analysis
of a real-world (RW) patient (pt) population using the Foundation
Medicine genomic database"
Poster Number: C019
Session Title: Poster Session C
Date/Time: Saturday, October 14,
2023, 12:30 pm-4:00 pm
Authors: David J. Kwiatkowski, MD, PhD, Norma A. Palma, PhD, Willis H. Navarro, MD, Gopa Iyer, MD
More information can be found on the AACR-NCI-EORTC
International Conference on Molecular Targets and Cancer
Therapeutics meeting website.
About Aadi Bioscience
Aadi is a commercial-stage biopharmaceutical company focused on
precision therapies for genetically defined cancers to bring
transformational therapies to cancer patients with mTOR pathway
driver alterations. Aadi received FDA approval in November
2021, and in February 2022 commenced commercialization of
FYARRO® for the treatment of adult patients with
locally advanced unresectable or metastatic malignant perivascular
epithelioid cell tumor (PEComa).
Aadi is conducting the PRECISION1 trial, a Phase 2
tumor-agnostic registration-directed study in patients with mTOR
inhibitor-naïve malignant solid tumors
harboring TSC1 or TSC2 inactivating
alterations. More information on Aadi's development pipeline is
available on the Aadi website at www.aadibio.com and
connect with us on Twitter and LinkedIn.
Contact:
Marcy
Graham
IR@aadibio.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/aadi-bioscience-announces-poster-presentations-at-2023-aacr-nci-eortc-international-conference-on-molecular-targets-and-cancer-therapeutics-301934004.html
SOURCE Aadi Bioscience